Investigational drug · Phase 3
IBP-9414
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Necrotizing Enterocolitis.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 12, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "IBP-9414"
First trial start
2019
Jul 4, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBP-9414", any sponsor or status.
Conditions studied
As listed on its trial records.
- Necrotizing Enterocolitis
Largest trials
Live from ClinicalTrials.gov: studies naming "IBP-9414" as an intervention, largest first.
- IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection StudyPivotal-lookingActive, not recruiting
Infant Bacterial TherapeuticsIndustry
NCT03978000 · 2,158 participants · Start Jul 4, 2019 · Primary completion Jun 2024
Drug: IBP-9414; Placebo · For: Necrotizing Enterocolitis
Sites: Tucson, Arizona; Little Rock, Arkansas; Loma Linda, California · 89 sites in all
- IBP-9414 for the Prevention of Necrotizing EnterocolitisPivotal-lookingCompleted
Infant Bacterial TherapeuticsIndustry
NCT02472769 · 120 participants · Start May 27, 2016 · Primary completion Aug 7, 2017
Drug: IBP-9414; Placebo · For: Necrotizing Enterocolitis
Sites: Little Rock, Arkansas; Los Angeles, California; Gainesville, Florida · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study.
Neu J, Del Moral T, Guthrie SO, et al. · Pediatr Res 2026
- Clinical Characteristics of Necrotizing Enterocolitis Diagnosed by Independent Adjudication of Abdominal Radiographs, Laparotomy, or Autopsy in Preterm Infants in the "Connection Trial".
Neu J, Singh R, Demetrian M, et al. · Am J Perinatol 2025
Also in development for Necrotizing Enterocolitis
- ST266Phase 21 trial
Noveome Biotherapeutics, formerly Stemnion · Necrotizing Enterocolitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.